{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:10:50Z","timestamp":1791846650567,"version":"4.3.4"},"reference-count":14,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"18","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,6,20]]},"abstract":"\n \n \n Taletrectinib is a next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor (TKI) with activity against the ROS1 G2032R resistance mutation. Initial data from the TRUST-I study (ClinicalTrials.gov identifier:\n NCT04395677<\/jats:ext-link>\n ) demonstrated high response rates and intracranial (IC) activity, with promising durability, in Chinese patients with advanced\n ROS1<\/jats:italic>\n + non\u2013small cell lung cancer (NSCLC). With longer follow-up, taletrectinib continued to demonstrate high and durable response rates in both TKI-na\u00efve and crizotinib-pretreated patients, including IC activity and promising overall survival (OS). Among 103 TKI-na\u00efve patients who started taletrectinib at 600 mg once daily (median follow-up, 51.0 months), the objective response rate (ORR) was 90.3% (95% CI, 82.9 to 95.3), the median duration of response (DOR) and median progression-free survival (PFS) exceeded 4 years (49.7 months and 49.6 months, respectively), and median OS was not reached. Among 66 crizotinib-pretreated patients (median follow-up, 45.2 months), the ORR was 51.5%, the median DOR was 13.2 months, the median PFS was 7.6 months, and the median OS was 25.6 months. The safety profile remained consistent with prior reports, and no new safety signals were identified. Overall, taletrectinib demonstrated durable long-term efficacy and a manageable safety profile in patients with advanced\n ROS1<\/jats:italic>\n + NSCLC.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/jco-26-00434","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:58:06Z","timestamp":1776808686000},"page":"1670-1675","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Efficacy and Safety of Taletrectinib in Patients With\n ROS1<\/i>\n + Non\u2013Small Cell Lung Cancer: Results From the Phase II TRUST-I Study"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct04395677","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7960-0372","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Fan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qitao","family":"Yu","sequence":"additional","affiliation":[{"name":"Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7478-8430","authenticated-orcid":false,"given":"Feiwu","family":"Ran","sequence":"additional","affiliation":[{"name":"Nuvation Bio Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Nuvation Bio Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-9941","authenticated-orcid":false,"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Shanghai East Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11496-z"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1059"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00275"},{"key":"e_1_3_11_5_2","volume-title":"IBTROZI (Taletrectinib) Prescribing Information","author":"Nuvation Bio Inc","year":"2025","unstructured":"Nuvation Bio Inc: IBTROZI (Taletrectinib) Prescribing Information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219713s000lbl.pdf"},{"key":"e_1_3_11_6_2","unstructured":"Nippon Kayaku Co Ltd: Nippon Kayaku announces IBTROZI\u00ae capsules 200 mg (taletrectinib) approved in Japan for unresectable advanced or recurrent ROS1-positive non-small cell lung cancer. 2025. https:\/\/www.nipponkayaku.co.jp\/english\/news\/detail.php?n=20250919_6G5AI1Y7"},{"key":"e_1_3_11_7_2","unstructured":"Nuvation Bio Inc: Nuvation bio receives approval from China\u2019s National Medical Products Administration for taletrectinib in advanced ROS1-positive non-small cell lung cancer. 2025. https:\/\/investors.nuvationbio.com\/news\/news-details\/2025\/Nuvation-Bio-Receives-Approval-from-Chinas-National-Medical-Products-Administration-for-Taletrectinib-for-Patients-with-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer\/default.aspx"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00731"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz131"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302299"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.12.001"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.931"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8643"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.105"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.1077"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-26-00434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:59:14Z","timestamp":1781647154000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-26-00434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":14,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,6,20]]}},"alternative-id":["10.1200\/JCO-26-00434"],"URL":"https:\/\/doi.org\/10.1200\/jco-26-00434","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"2026-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}